Should informed consent be required for laboratory testing for drugs of abuse in medical settings?

American Journal of Medicine

Volumn 115, Issue 1, 2003, Pages 54-58

  Warner, Elizabeth A ^a   Walker, Robert M ^b   Friedmann, Peter D ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFIDENTIALITY; DIAGNOSTIC ACCURACY; DOCTOR PATIENT RELATION; DRUG ABUSE; DRUG DEPENDENCE; HUMAN; IMMUNOASSAY; INFORMED CONSENT; LABORATORY TEST; LEGAL ASPECT; MEDICAL ETHICS; PRIORITY JOURNAL; PRIVACY; REVIEW;

EID: 0037966131     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(03)00236-5     Document Type: Review

References (34)

1. Warner E.A. Laboratory diagnosis. Graham A.W., Schultz T.K., Mayo-Smith M., et al. Principles of Addiction Medicine. 3rd ed: 2003;337-348 American Society of Addiction Medicine, Chevy Chase, Maryland.
2. Soderstrom C.A., Smith G.S., Dischinger P.C., et al. Psychoactive sub-stance use disorders among seriously injured trauma center patients. JAMA. 277:1997;1769-1774.
3. Screening for Alcohol and Other Drug Use in Trauma Patients. 1991;American Medical Association, Chicago, Illinois. Report No. H-130.956.
4. Lange R.A., Hillis L.D. Cardiovascular complications of cocaine use. N Engl J Med. 345:2001;351-358.
5. Brett A.S. Implications of discordance between clinical impression and toxicology analysis in drug overdose. Arch Intern Med. 148:1988;437-441.
6. Warner E.A., Green G.S., Buchsbaum M.S., et al. Diabetic ketoacidosis associated with cocaine use. Arch Intern Med. 158:1998;1799-1802.
7. Kellermann A.L., Fihn S.D., LoGerfo J.P., Copass M.K. Impact of drug screening in suspected overdose. Ann Emerg Med. 16:1987;1206-1216.
8. Bast R.P., Helmer S.D., Henson S.R., et al. Limited utility of routine drug screening in trauma patients. South Med J. 93:2000;397-399.
9. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 106:2002;1893-1900.
10. Gentilello L.M., Duggan P., Drummond D., et al. Major injury as a unique opportunity to initiate treatment in the alcoholic. Am J Surg. 156:1988;558-561.
11. Warner E.A. A profile of hospitalized cocaine users patient characteristics, diagnoses, and physician responses . Subst Abuse. 16:1995;205-212.
12. Wolff K., Farrell M., Marsden J., et al. A review of biological indicators of illicit drug use, practical considerations and clinical usefulness. Addiction. 94:1999;1279-1298.
13. Colbert D.L. Drug abuse screening with immunoassays unexpected cross-reactivities and other pitfalls . Br J Biomed Sci. 51:1994;136-146.
14. Kraemer T., Maurer H.H. Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine. J Chromatogr B Biomed Sci Appl. 713:1998;163-187.
15. Hayes L.W., Krasselt W.G., Mueggler P.A. Concentrations of morphine and codeine in serum and urine after ingestion of poppy seeds. Clin Chem. 33:1987;806-808.
16. Huestis M.A., Mitchell J.M., Cone E.J. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol. 19:1995;443-449.
17. Ellis G.M.J., Mann M.A., Judson B.A., Schramm N.T., Tashchian A. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther. 38:1985;572-578.
18. Urine Specimen Collection Handbook for Federal Workplace Drug Testing. 1996;U.S. Department of Health and Human Services, Rockville, Maryland.
19. U.S. Department of Health and Human Services: mandatory guidelines for federal workplace drug testing programs, 59 Federal Register29908 (1994).
20. U.S. Department of Health and Human Services: mandatory guidelines for federal workplace drug testing, 62 Federal Register 5118 (1997).
21. Rostenberg PO. Alcohol and Other Drug Screening of Hospitalized Trauma Patients. Rockville, Maryland: U.S. Department of Health and Human Services; 1995. Treatment Improvement Series.
22. Rivara F.P., Tollefson S., Tesh E., Gentilello L.M. Screening trauma patients for alcohol problems: are insurance companies barriers? J Trauma. 48:2000;115-118.
23. National Clearinghouse on Child Abuse and Neglect Information. U.S. Department of Health and Human Services. Available at: http://www.calib.com/nccanch. Accessed February 14, 2003.
24. Roe v. Wade, U.S. 113 (1973).
25. Katz J. The Silent World of Doctor and Patient. 1984;Free Press, New York, New York.
26. Jonsen A.R., Siegler M., Winslade W.J. Clinical Ethics. 3rd ed: 1992;McGraw-Hill, New York, New York.
27. Annas G.J. Testing poor pregnant women for cocaine - physicians as police investigators. N Engl J Med. 344:2001;1729-1732.
28. Lewis C.E., Montgomery K. The HIV-testing policies of US hospitals. JAMA. 264:1990;2764-2767.
29. Miesfeldt S., Jones C.M., Cohn W.F. Informed consent for BRCA1 and BRCA2 testing what clinicians should know about the process and content . J Am Med Womens Assoc. 55:2000;275-279.
30. Confidentiality of alcohol and drug abuse patient records (codified at 42 CFR Part 2 §2).
31. Florida Statutes 397.501.
32. U.S. Department of Health and Human Services: standards for privacy of individually identifiable health information (45 CFR Parts 160 and 164).
33. Testing for drugs of abuse in children and adolescents. Pediatrics. 98:1996;305-307.
34. Samet J.H., Rollnick S., Barnes H. Beyond CAGE. A brief clinical approach after detection of substance abuse. Arch Intern Med. 156:1996;2287-2293.